Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | MAP2K1 K57T |
Therapy | Cetuximab |
Indication/Tumor Type | colorectal cancer |
Response Type | predicted - resistant |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
MAP2K1 K57T | colorectal cancer | predicted - resistant | Cetuximab | Case Reports/Case Series | Actionable | In a clinical case study, a patient with colorectal cancer developed liver metastases harboring MAP2K1 K57T that were insensitive to Erbitux (cetuximab) treatment and the mutation was confirmed to cause resistance in human colorectal cancer cell lines in culture (PMID: 26644315). | 26644315 |
PubMed Id | Reference Title | Details |
---|---|---|
(26644315) | Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer. | Full reference... |